How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins?

Curtis L Triplitt, Debbie Hinnen, Virginia Valentine

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-on” biological products is likely to increase in routine clinical practice. Health care practitioners need to be fully aware of these products and accompanying considerations if they are to make informed decisions together with their patients.

Original languageEnglish (US)
Pages (from-to)209-216
Number of pages8
JournalClinical Diabetes
Volume35
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Biosimilar Pharmaceuticals
Insulins
Delivery of Health Care
Patents
Biological Products

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins? / Triplitt, Curtis L; Hinnen, Debbie; Valentine, Virginia.

In: Clinical Diabetes, Vol. 35, No. 4, 01.10.2017, p. 209-216.

Research output: Contribution to journalArticle

Triplitt, Curtis L ; Hinnen, Debbie ; Valentine, Virginia. / How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins?. In: Clinical Diabetes. 2017 ; Vol. 35, No. 4. pp. 209-216.
@article{eaab05df391442669c26166f0668504e,
title = "How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins?",
abstract = "As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-on” biological products is likely to increase in routine clinical practice. Health care practitioners need to be fully aware of these products and accompanying considerations if they are to make informed decisions together with their patients.",
author = "Triplitt, {Curtis L} and Debbie Hinnen and Virginia Valentine",
year = "2017",
month = "10",
day = "1",
doi = "10.2337/cd16-0072",
language = "English (US)",
volume = "35",
pages = "209--216",
journal = "Clinical Diabetes",
issn = "0891-8929",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins?

AU - Triplitt, Curtis L

AU - Hinnen, Debbie

AU - Valentine, Virginia

PY - 2017/10/1

Y1 - 2017/10/1

N2 - As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-on” biological products is likely to increase in routine clinical practice. Health care practitioners need to be fully aware of these products and accompanying considerations if they are to make informed decisions together with their patients.

AB - As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-on” biological products is likely to increase in routine clinical practice. Health care practitioners need to be fully aware of these products and accompanying considerations if they are to make informed decisions together with their patients.

UR - http://www.scopus.com/inward/record.url?scp=85032874590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032874590&partnerID=8YFLogxK

U2 - 10.2337/cd16-0072

DO - 10.2337/cd16-0072

M3 - Article

AN - SCOPUS:85032874590

VL - 35

SP - 209

EP - 216

JO - Clinical Diabetes

JF - Clinical Diabetes

SN - 0891-8929

IS - 4

ER -